Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + chiauranib
- Development stage
- Discontinued
- Lead developer
- Akeso
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of capecitabine and chiauranib being investigated for the treatment of advanced triple-negative breast cancer (TNBC) that has failed prior anthracyclines and taxanes therapy. Capecitabine is a fluoropyrimidine carbamate prodrug that is converted to 5-fluorouracil (5-FU) by enzymes expressed in higher concentrations in tumors. Chiauranib is a novel multi-targeted kinase inhibitor that simultaneously inhibits angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRa, and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R.
02
Targets
AURKB (Aurora kinase B)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)DDR1 (Discoidin domain receptor 1)
Beyond the preview
Go deeper on capecitabine + chiauranib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + chiauranib.